License and Cooperation Agreement FOR PERIFOSINE by and between Zentaris AG Weismüllerstr. 45 60314 Frankfurt am Main Germany - herein “Zentaris” - and AOI Pharma, Inc. 750 Lexington Avenue, 26th Floor New York, New York 10022 USA - herein “AOI” -License and Cooperation Agreement • March 30th, 2010 • Aeterna Zentaris Inc. • Pharmaceutical preparations
Whereas, AOI desires to obtain certain licenses from Zentaris to develop and commercialize Perifosine under the aforesaid patents and know-how, and Zentaris is willing to grant to AOI such licenses;
OMITTED INFORMATION IS THE SUBJECT OF A REQUEST FOR CONFIDENTIAL TREATMENT PURSUANT TO RULE 24B-2 UNDER THE SECURITIES EXCHANGE ACT OF 1934 AND HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSIONLicense and Cooperation Agreement • March 30th, 2010 • Aeterna Zentaris Inc. • Pharmaceutical preparations
Æterna Zentaris GmbH (formerly Zentaris AG) and AOI Pharma, Inc., a wholly-owned subsidiary of Keryx Biopharmaceuticals, Inc. are parties to a License and Cooperation Agreement for Perifosine dated September 18, 2002 (the “Agreement”). The parties wish to amend the Agreement as follows:
OMITTED INFORMATION IS THE SUBJECT OF A REQUEST FOR CONFIDENTIAL TREATMENT PURSUANT TO RULE 24B-2 UNDER THE SECURITIES EXCHANGE ACT OF 1934 AND HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION.Addendum Agreement to License and Cooperation Agreement • March 30th, 2010 • Aeterna Zentaris Inc. • Pharmaceutical preparations
WHEREAS, AOI and Zentaris have entered into a License Agreement for Perifosine dated September 18, 2002 regarding the development, manufacturing and commercialization of Perifosine (“License Agreement”). This addendum is made to define the agreement of the Parties with respect to the Pharmaceutical Development of Perifosine API and Perifosine Drug Product.
